CytomX Therapeutics (CTMX) EBT (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of EBT data on file, last reported at -$18.2 million in Q1 2026.

• Quarterly EBT fell 177.11% year-over-year to -$18.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.9 million (down 240.79% YoY) and the FY2025 annual result came in at -$17.1 million, down 153.38% from the prior year.
• EBT rose to -$18.2 million in Q1 2026, from -$26.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of $23.6 million in Q1 2025 to a low of -$32.0 million in Q1 2022.
• A 5-year average of -$5.8 million and a median of -$3.3 million in 2023 frame the typical range for EBT.
• The widest YoY moves for EBT: up 893.6% in 2024, down 496.41% in 2024.
• Tracing CTMX's EBT over 5 years: stood at -$8.8 million in 2022, then surged by 121.72% to $1.9 million in 2023, then soared by 893.6% to $18.9 million in 2024, then plunged by 239.7% to -$26.5 million in 2025, then surged by 31.25% to -$18.2 million in 2026.
• The last three EBT figures came in at -$18.2 million (Q1 2026), -$26.5 million (Q4 2025), and -$14.2 million (Q3 2025), per Business Quant data.